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Abstract
The interferon-stimulated gene viperin has been shown to have antiviral activity against hepatitis
C virus (HCV) in the context of the HCV replicon, although the molecular mechanisms
responsible are not well understood. Here we demonstrate that viperin plays an integral part in the
ability of interferon to limit replication of cell culture derived HCV (JFH-1) that accurately
reflects the complete viral life cycle. Using confocal microscopy and Fluorescence Resonance
Energy Transfer (FRET) analysis we demonstrate that viperin localizes and interacts with HCV
NS5A at the lipid droplet interface. In addition viperin also associates with NS5A and the pro-
viral cellular factor, VAP-A at the HCV replication complex. The ability of viperin to limit HCV
replication was dependent on residues within the C-terminus as well as an N-terminal amphipathic
helix. Removal of the amphipathic helix redirected viperin from the cytosolic face of the ER and
the lipid droplet to a homogenous cytoplasmic distribution, coinciding with a loss of antiviral
effect. C-terminal viperin mutants still localized to the lipid droplet interface and replication
complexes but did not interact with NS5A proteins as determined by FRET analysis. In conclusion
we propose that viperin interacts with NS5A and the host factor VAP-A to limit HCV replication
at the replication complex. This highlights the complexity of host control of viral replication by
interferon stimulated gene expression.
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Hepatitis C virus (HCV) is a leading cause of chronic hepatitis and liver-related morbidity
worldwide. A significant proportion of infected individuals fail to develop an effective host
antiviral response and develop a chronic infection, often resulting in a progressive liver
disease including cirrhosis and hepatocellular carcinoma (1). The current standard-of-care
therapy for chronic hepatitis C (CHC) is a combination of pegylated interferon alpha (IFN-
α) and ribavirin that results in sustained viral clearance in at best 50% of patients.
Viral infection of mammalian cells results in activation of a number of viral recognition
pathways triggered by replication intermediates and/or viral proteins, that ultimately induce
innate defences to limit viral replication (2-4). Pivitol to this antiviral response is the
induction of IFN. The type I IFN's (IFN-α and β) are essential for immune defences against
viruses, and following binding to the type I IFN receptor induce the expression of hundreds
of interferon-stimulated genes (ISGs), many of which act to limit viral replication. While a
number of these ISGs have well characterised antiviral activity (i.e., MxA, PKR and 2,5-
OAS), the complete spectrum of antiviral ISGs and their mechanisms of action remain to be
elucidated (3).
The ISGs responsible for controlling HCV replication in response to IFN (either
endogenously induced or therapeutically given) remain ill defined, although a picture of the
ISG's capable of controlling HCV replication is emerging. The ISG 2,5-OAS has been
shown to inhibit HCV replication through the RNAse L pathway (5), while IFN-α mediated
suppression of HCV replication in vitro is independent of MxA (6). A number of less well
characterised ISGs have also been demonstrated to inhibit HCV replication; studies have
demonstrated that ISG6-16 can enhance the anti-HCV activity of IFN-α (7), while ISG56
has direct anti-HCV activity through its ability to suppress HCV IRES translation (8). More
recently, PKR and the 3′-to-5′ exonuclease ISG20 have been demonstrated to inhibit HCV
replication (9, 10). Clearly anti-HCV ISG effectors remain to be discovered and
characterised.
Viperin is an evolutionarily conserved type I ISG, previously demonstrated by our
laboratory and others to have antiviral properties against HCV in vitro (9, 11), and a number
of other viruses including human cytomegalovirus (HCMV), influenza, alphaviruses, HIV
and dengue (reviewed in 12). However, the mechanism by which viperin exerts its anti-HCV
effect is unknown. Viperin localizes to both the ER and lipid droplets (LD) and considering
the LD is central to the HCV life cycle it has been hypothesised that viperin inhibits HCV
replication at this location (12, 13). In this study, we show that viperin suppresses replication
of cell culture derived infectious HCV, and demonstrate for the first time that viperin
interacts with the NS5A protein at the LD interface and within the replication complex (RC).
Furthermore we also show that viperin co-localizes with the known proviral cellular factor,




The human hepatoma cell lines Huh-7, Huh-7.5 (Charles Rice, Rockefeller University, NY,
USA), NNeoC5B and NNeo3-5B (14) were maintained as previously described (15). Huh-7
cells stably expressing viperin shRNA were generated using a 5 clone shRNA set in pLKO.1
purchased from Open Biosystems (Thermo Scientific, AL, USA). These constructs,
including a shRNA control were co-transfected with the packaging vectors psPAX2 and
pMD2.G into 293T cells to generate VSV-G pseudotyped lentiviral particles. Supernatants
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containing virus were pooled 48 and 72 hrs after transfection, 0.45μm filtered and placed on
Huh-7 cells at a ratio of 1:5 with standard culture media and 8μg/ml polybrene. Polyclonal
cell populations were selected with 3μg/ml puromycin. Knockdown of viperin expression
was confirmed by treatment of selected polyclonal cell lines with 10 and 50 U/ml of IFN-α,
and real-time PCR utilized to assess the upregulation of viperin compared to the control
shRNA cell line.
Viruses and antibodies
Infectious genotype 2a JFH-1 HCV was prepared as previously described (16, 17). The
HCV monoclonal NS5A antibody (9E10) was a kind gift from Charles Rice. The mouse
monoclonal HCV core (C7-50) antibody was purchased form Abcam (Cambridge, MA,
USA). Mouse monoclonal anti-FLAG, rabbit polyclonal anti-FLAG and goat anti-GFP
biotinylated antibodies were respectively obtained form Sigma (St Louis, MO, USA) and
Rockland (Gilbertsville, PA, USA). Rabbit polyclonal viperin antibodies were generated as
previously described (18). Bodipy 493/503 (Invitrogen, Carlsbad, CA, USA) was prepared
as a stock solution of 1 mg/ml in ethanol.
Plasmids and transfections
Human FDPS was amplified from human liver cDNA, and cloned into pLNCX2 between
Not I and Xba I using the following primers: 5′- attcgcggccgcatgcccctgtcccgctggttgagatc-3;
and 5′-aacctctagatcaagcgtagtctgggacgtcgtatgggtactttctccgcttgtagattttgcgcgcaag-3′,
engineering it to contain a 3′-HA tag. pLenti6-mCherry was generated by cloning mCherry
cDNA (lacking a stop codon) into BamHI and XhoI sites of pLenti6/V5-D-TOPO
(Invitrogen). Human VAP-A (transcript variant 2) and Rab5A cDNA were PCR-amplified
from Huh-7.5 cell cDNA using the following oligonucleotides (restriction sites are
italicized): VAP-A (5′- catctcgagctatggcgtccgcctcaggg-3′ and 5′-
ggtacgcgttgcatgcttcactctacaagatgaatttc-3′) and Rab5A (5′-
catctcgagcttcaaccatggctagtcgaggcgcaa-3′ and 5′- ggtacgcgtttagttactacaacactgattcct-3′) and
cloned, in-frame, into XhoI and MluI sites of pLenti6-mCherry. The expression plasmid
pHalo-PI4K-IIIα was purchased from Promega (Kazusa DNA Research Institute clone
pFN21AB1434). pEGFPC1-ALDI, pEGFPC1-ADRP were generously provided by Albert
Pol (University of Barcelone, Barcelona, Spain), John McLauchlan (MRC Virology Unit,
Glasgow, UK) respectively. The human viperin plasmid has previously been described (11),
and mutant versions of the plasmid were constructed in pLNCX2 either via mutagenesis
PCR utilising a QuickChange mutagenesis II system (Stratagene, CA, USA) or via PCR
cloning using the HindIII and NotI sites and 5′FLAG tagging the constructs, using the
primers listed in table 1. Transfection of all plasmids was performed using Fugene6 (Roche,
NJ, USA) according to the manufacturers' recommendations.
Real-time polymerase chain reaction
All experiments involving real-time PCR were performed in 12 well plates with Huh-7 cells
seeded at 8 × 104/well, 24 hours prior to transfection/infection, and performed at least in
triplicate. RNA was extracted from cells using Trizol reagent (Invitrogen). First strand
cDNA was synthesized from total RNA and real-time PCR analysis was utilised to
quantitate the relative levels of HCV RNA and viperin mRNA in comparison to the house
keeping gene RPLPO. Reaction conditions and primers are as described previously (11).
Immunofluorescence staining
Huh-7 cells were seeded on 0.2% gelatin coated cover slips in 24 well trays (4 × 104 cells/
well) 24 hrs prior to transfection/infection. Cells were either fixed using methanol/acetone
(1:1) for 5 minutes on ice for standard microscopy, or with 4% paraformaldehyde for 10
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minutes on ice followed by a 10 minute incubation in 0.1% Triton-X in PBS for confocal
microscopy; prior to incubation with primary antibodies for 1 hr at RT. Cells were washed
in PBS and incubated with secondary antibodies for 1 hr at RT before being mounted with
Prolong Gold reagent (Invitrogen). Images were acquired with a Bio-Rad Radiance 2100
Confocal or a Nikon TiE inverted microscope.
Fluorescence Energy Resonance Transfer (FRET) analysis
Acceptor photobleaching was carried out essentially as described in (19) with the use of
Alexa555 (Invitrogen) and Cy5 (Jackson laboratories, Westgrove, PA, USA) conjugated
secondary antibodies or GFP and mCherry tagged protein constructs. Images of the acceptor
and donor flurophores were acquired using a Zeiss Axioplan2 upright microscope, using a
63X PlanApo objective. Acceptor photobleaching was performed at maximum light
intensity for 30-180 sec, followed by re-imaging of the donor and acceptor fluorophores
(this was an automated process ensuring identical imaging conditions). The FRET signal
(increase in signal postbleach) was determined by the subtraction of the pre- from
postbleach donor image using Image J software (20). Lipid droplets and putative replication
complexes positive for both proteins being examined were selected and the average intensity
in that region was compared on the aligned pre- and postbleach images (the plug-in
StackReg was utilized to control for lateral image displacement, and the FRET signal was
displayed using the ‘fire’ lookup table). Multiple lipid droplets and /or cytoplasmic foci that
were positive for both proteins being measured were examined from at least 10 different
cells in each of at least two independent experiments to ensure reproducibility. Negative
slides were prepared by either omitting the primary antibody for the acceptor molecule or in
the case of the GFP/mCherry FRET imaging cells with only the donor molecule present.
Luciferase assays
Luciferase assays were performed as previously mentioned (10, 21). Briefly, Huh-7 cells
were seeded at 8 × 104 in 12 well plates 24 hours prior to transient transfection using
Fugene, with either pLNCX2-viperin, pLNCX2-viperin3′Δ17 or empty vector. 24 hours
following transfection, cells were transfected using 2μg of in vitro transcribed RNA
(DMRIE-C) representing SGRm-JFH1BlaRL (10). Input renilla luciferase was measured at
3 hrs post RNA transfection to obtain a background reading, with further measurements
being taken at 24 and 48 hrs. All time points were performed in quadruplicate. Luciferase
assays involving the dicistronic reporter plasmid, pRLHL (21) were performed in a similar
manner, with firefly and renilla luciferase measured at 24 hrs post vector transfection. RLuc
is translated via cap-dependent translation, whereas the translation of FLuc is directed by the
HCV IRES.
Statistical analysis
Student t-tests were utilised to analyse the distributions of 2 normally distributed data sets.
All statistical analysis was performed using SPSS 10.
Results
Viperin is induced during HCV infection of Huh-7 cells and inhibits replication
We have previously demonstrated that viperin mRNA expression in Huh-7 cells is
responsive to either the dsRNA analogue poly I:C or in vitro transcribed HCV RNA (11). To
extend these observations in the context of the complete HCV life-cycle, we infected Huh-7
cells with HCV JFH-1 and monitored viperin mRNA expression. Viperin mRNA expression
was significantly increased (∼25 fold) at 72 hrs post infection which coincided with an
increase in HCV RNA (Fig 1A). Interestingly similar experiments performed in the Huh7.5
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cell line which is defective in dsRNA signaling via a mutation in the pathogen-recognition
receptor RIG-I (22), showed only a slight increase in viperin mRNA expression, even
though greater than 95% of cells were infected (Fig 1B and Fig S1), implying that its
expression in the Huh-7's was RIG-I mediated. We also extended our previous results using
the HCV replicon system to show that following transient expression of viperin, HCV JFH-1
replication is inhibited by approximately 45% (Fig 1C). Interestingly, dual immunostaining
for both HCV antigen (NS5A) and viperin revealed few cells expressing both antigens, even
though control cells were approximately 90% positive for HCV (Figure 1D). In those cells
expressing both NS5A and viperin a much lower level of HCV NS5A expression was noted
(Fig 1D arrows). These results confirm the anti-HCV activity of viperin using the more
physiologically relevant JFH-1 infectious virus system.
shRNA knockdown of viperin reduces the antiviral effect of IFN-α
To determine if endogenous viperin has anti-HCV activity following IFN-α stimulation we
created a number of polyclonal Huh-7 cell lines stably expressing shRNA targeting viperin
mRNA (Fig S2). The cell line Vip shRNA#5 compared to a control cell line expressing non-
specific shRNA produced significantly less viperin mRNA following IFN-α stimulation (Fig
1E, *p < 0.001). Vip shRNA#5 cells stimulated for 24 hrs with varying concentrations of
IFN-α had approximately 90-95% less viperin mRNA than their control counterparts. The
Vip shRNA#5 cells were then either pre-treated with IFN-α for 24 hours before JFH-1
infection, or treated with IFN-α for 24 hours following JFH-1 infection. As can be seen in
Figure 1F, the control cell line was able to reduce HCV replication levels by 69 and 66%
respectively following either pre- or post- IFN-α treatment, whereas the Vip shRNA#5 cell
line was only able to reduce HCV replication by 45 and 37% respectively under the same
conditions. These results demonstrate that viperin plays an important, but not exclusive role
in the antiviral effects of IFN-α against HCV in vitro.
Viperin interacts with HCV core and NS5A
Previous reports suggest that viperin localises to the ER (18, 23), however we and others
have observed that viperin also localises to lipid droplets (LD) in Huh-7 cells (Fig S3 and
S4)(24). The LD plays an important role in the HCV life cycle as both core and NS5A
localise to the LD surface (25). With this in mind we investigated the distribution of viperin,
HCV core and NS5A in Huh-7 cells productively infected with JFH-1 using confocal
microscopy. These studies revealed considerable but not absolute co-localisation between
viperin and both core and NS5A proteins, surrounding LDs (Fig 2A). In addition viperin
also co-localised with NS5A in a proportion of small cytoplasmic foci that have been well
characterised as part of the HCV replication complex (RC) (26) (arrow heads in Figure 2B).
Next we investigated localisation of viperin and NS5A in cells harbouring a HCV
subgenomic replicon that are devoid of the HCV structural proteins. In these cells viperin
co-localised with NS5A in a similar manner to that observed for JFH-1 infected cells with
co-localisation of viperin and NS5A at the RC and LD surface (Fig 2C inset), although the
latter was not as pronounced as in JFH-1 infection. This suggests that viperin may exert its
antiviral effect through a possible interaction with NS5A either within the RC or at the LD
surface. To extend our confocal microscopy results and to determine if viperin physically
interacts with NS5A and core, fluorescence energy resonance transfer (FRET) was utilised.
Even though viperin and ADRP co-localise by confocal analysis no positive FRET was
observed (Fig 3A) indicating that it is unlikely these two proteins physically interact. In
contrast, Huh-7 cells infected with JFH-1 displayed significant FRET at the LD surface
between viperin and either HCV core or NS5A, in addition to positive FRET with NS5A
within the HCV RC (Fig 3B and C). Collectively these results strongly suggest that viperin
is able to interact with core and NS5A on the LD surface and with NS5A within the RC.
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Mutagenic analysis reveals important regions of viperin for anti-HCV activity
Little is known about the functional aspects of viperin that contribute to its antiviral activity.
Recent work has demonstrated that viperin is able to bind the enzyme FDPS and interrupt
the mevalonate pathway, causing a restriction in influenza budding from lipid rafts (23).
Restoration of this pathway did not rescue HCV replication in viperin expressing cells,
thereby indicating an alternative anti-viral mechanism for the protein in the context of HCV
(Fig S6).
Viperin is a member of the radical SAM family of enzymes (27), and contains 4 radical
SAM motifs in addition to a putative leucine zipper domain, which may be of importance in
protein-protein interactions. In order to further understand the anti-HCV mechanism of
viperin, mutations were made to destabilise the leucine and SAM1-4 domains (Figure 4A).
In contrast to previous reports (9), all viperin mutations retained anti-HCV activity in JFH-1
infected Huh-7 cells (Fig 5B, M1-4). Next we created a panel of deletion mutants from the
N- and C-termini of viperin (Figure 4A). Deletion of 33 aa or 17 aa from the N and C
termini respectively, abrogated viperin's anti-HCV function, (Fig 4B). Interestingly,
coincident with loss of anti-HCV activity for the N-terminal deletions was a redistribution of
viperin from the LD's and ER to a homogeneous cytoplasmic pattern (Fig 4C). This is not
entirely unexpected given the presence of a N terminally located amphipathic-alpha helix
(13), which is thought to allow peripheral proteins to anchor into the ER, induce curvature of
the ER and bind lipid droplet surfaces (28). In contrast to previous reports (9), the 6 terminal
aa were not required for anti-viral activity (Fig 4B and Fig S5). However, deletion of 10aa
abrogated the anti-HCV action of viperin.
In contrast to N-terminal deletions, C-terminal truncations of viperin localised to the ER and
LD (Figure 4C) and co-localised with HCV core and NS5A (Figures 5A and 5B), even
though its antiviral activity had been abrogated (Fig 4B). FRET analysis of JFH-1 infected
Huh-7 cells expressing the 3′Δ17 viperin mutant revealed that viperin was no longer
associated with either HCV core or NS5A (Fig 5A and B).
Collectively these results demonstrate that the final 10aa of the C-terminal region of viperin
are essential for its ability to limit intracellular HCV RNA levels through interaction with
HCV NS5A and/or core.
Viperin interrupts HCV replication
Given the ability of viperin to limit the HCV subgenomic replicon (Fig 1C), and its
interaction with NS5A within the RC (Fig 3B) we hypothesised that viperin was acting at
the level of HCV RNA replication. To investigate the mechanism of viperin action in more
detail we used a subgenomic HCV replicon that encodes the renilla luciferase reporter gene
(SGRm-JFH1BlaRL) that allows us to investigate the kinetics of HCV RNA replication
uncoupled from virion assembly (10). Compared to control (empty plasmid) or a viperin 3′
deletion mutant that has no antiviral activity (pLNCX2-viperin3′Δ17), cells transfected with
WT viperin expressing plasmid revealed a significant decrease in Renilla output (p = 0.005)
at 48 hours post transfection (Fig 6A). We also discounted any effect of viperin on HCV
IRES directed translation (Fig 6B). Collectively these results suggest that viperin acts at the
level of HCV RNA replication via a direct interaction of viperin with NS5A at the RC.
Viperin co-localizes with VAP-A, a known NS5A interacting cellular factor
A number of cellular factors, including Rab5a, VAP-A and the ER lipid kinase PI4K-IIIa are
essential for HCV replication and co-localize with NS5A at the RC (29, 30). We therefore
investigated the potential for interaction between the above mentioned factors and viperin
using confocal microscopy. In the absence of productive HCV infection, viperin co-
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localized with VAP-A, but not Rab5a or PI4K-IIIa (Fig 7A). To investigate the significance
of the viperin/VAP-co-localization in the context of HCV replication, FRET analysis
between viperin and VAP-A was performed in Huh-7 cells harbouring the HCV full length
genomic replicon. Viperin was found to positively interact with VAP-A in small
cytoplasmic foci representing RC's (Fig 7B). These results confirm that viperin/NS5A
cytoplasmic structures are RC's and suggest that the interaction of viperin with VAP-A at
the RC may destabalise HCV RNA replication.
Discussion
The standard treatment for chronic hepatitis C is IFN-α2/ribavirin combination therapy,
however at the molecular level its mode of action is not well understood. In individuals that
clear HCV following IFN therapy there is a rapid first phase of decline lasting
approximately 1–2 days, followed by a slower second phase of decline (31). This early
decline suggests that IFN has a direct effect on HCV replication via expression of antiviral
ISGs in infected hepatocytes. This observation has been validated in vitro with IFN-α
treatment of replicon cells resulting in a dose dependant decrease in HCV RNA (32, 33)
while long-term treatment with IFN-α can completely cure these cells of HCV replication
(34). However the ISGs responsible for this decrease in HCV RNA are not well
characterised. Considering that hundreds of ISGs are induced following IFN stimulation, a
systematic approach is required to identify novel ISGs with antiviral activity.
We previously identified the ISG viperin as being significantly expressed in the HCV
infected liver and subsequently demonstrated viperin to have anti-HCV activity (11). In this
study we now show that viperin is antiviral in the context of the complete HCV life cycle.
Consistent with viperin being an ISG we also observed that in Huh-7 cells there was a
significant increase in viperin mRNA following infection with HCVcc (JFH-1). Interestingly
this increase in viperin mRNA was not seen in Huh-7.5 cells that are highly permissive for
HCV infection and are defective in the dsRNA sensing molecule RIG-I. This strongly
suggests that viperin expression is induced through the cellular innate dsRNA response and
subsequent interferon production that feeds back to induce viperin expression through IRF3
and ISGF3 dependent mechanisms (35, 36). To confirm viperin's anti-HCV activity we
knocked down viperin expression using an RNAi approach and were able to demonstrate for
the first time that viperin plays an important but not exclusive role in the anti-HCV activity
of IFN-α. Considering that many genes are differentially regulated in Huh-7 cells following
IFN-α stimulation it is highly likely that a coordinated ISG response is responsible for
control of HCV replication.
A number of studies have suggested that viperin has an ER distribution (18, 23), however,
we and others have observed that viperin localises to both LDs and in our studies the HCV
NS5A positive RCs (24). LDs have recently been shown to be an essential component of the
HCV life cycle (25) and it is thought that the close association of the LD and ER membranes
provides a microenvironment that is essential for HCV RNA replication and virion
production. It has been hypothesized that the interaction of viperin with NS5A at the LD
surface is the possible mechanism whereby viperin exerts its antiviral effect through
disruption of virion assembly (12, 13). However, a number of lines of evidence suggest that
this is unlikely. Firstly, viperin exerts its anti-HCV effect against the HCV subgenomic
replicon, that lacks the HCV structural proteins and is defective in virion assembly. This
would also suggest that the viperin-core interaction we observed is not fundamental to
viperins antiviral activity, and that the interaction with NS5A is critical. It is plausible that
the observed interaction between viperin and core at the surface of the LD is mediated by
the ability of core to recruit and interact with NS5A at the LD surface to initiate virion
assembly. Secondly, viperin is antiviral against a genotype 2a HCV subgenomic replicon
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(SGRm-JFH1BlaRL) in which the HCV IRES drives expression of the luciferase reporter
gene to allow for quantitative measurement of HCV RNA replication kinetics uncoupled
from virion assembly, following transfection of in vitro transcribed HCV RNA (10).
Expression of viperin significantly suppressed luciferase output from this HCV subgenomic
replicon suggesting that the anti-HCV effect of viperin was at the level of HCV replication
and not virion assembly. Finally, through confocal miscroscopy and FRET analysis we have
conclusively shown that viperin interacts with both NS5A and the pro-viral host factor VAP-
A within the HCV RC. VAP-A (also known as hVAP-33) is a known interacting partner
with NS5A (and NS5B) and required for the efficient replication of HCV genomic RNA
(30). While the exact mechanism of how VAP-A enhances HCV replication is unknown,
VAP-A is involved in the regulation, biosynthesis and trafficking of sterols and lipids and is
thought to be involved in the formation of the HCV RC (30). Thus based on our
observations it is conceivable to envisage that viperin interacts with VAP-A at the HCV RC
and that this interaction perturbs the association of NS5A with VAP-A that is essential for
efficient viral RNA replication.
In this study we have shown that the ISG viperin is physically associated with the HCV
NS5A and core proteins at LD interface while interacting with the pro-viral host factor
VAP-A at the HCV RC. Through mutational analysis of viperin we have also demonstrated
that the presence of the N-terminal amphipathic helix of viperin is important to localize the
protein to the LD and RC, and that the C-terminal region of viperin is essential for its ability
to interact with NS5A and exert its anti-HCV action. Furthermore, we have demonstrated
that viperin is antiviral against HCV JFH-1 and the HCV subgenomic replicon (genotype 1b
and 2a) suggesting that the interaction with core protein is not essential for its antiviral
activity. This strongly implicates the association of viperin with NS5A and VAP-A at the
RC as the site where viperin exerts its novel antiviral activity through altering the stability
and/or functionality of the HCV RC. Interestingly, while the list of viruses towards which
viperin exerts its antiviral effect on is growing, its mode of action is unique in many cases
highlighting the complexity of this multi-functional protein. This work adds to our
understanding of the viral host interaction and the hepatocyte response to overcome viral
infection. Moreover, defining the mechanism of action of these ISGs will add to our
understanding of HCV replication and may present novel therapeutic strategies for chronic
hepatitis C.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Viperin is antiviral and important in the anti-HCV properties of IFN
(A and B) Expression of viperin in HCV infected Huh-7 and Huh-7.5 cells. Cells were
infected with JFH-1 at an MOI of 0.03 and the RNA harvested for Real-time PCR at the
indicated time points. (Data are represented as mean + SEM) (C) Viperin expression limits
HCV replication. Huh-7 cells were transfected with pLNCX2-viperin 24 hrs prior to JFH-1
infection (MOI =0.03), and RNA harvested 24 hrs post infection. HCV replicon cells were
transfected with pLNCX2-viperin and cell sorted for positive expression 48 hrs post
transfection. (Data are represented as mean +/- SEM with a significance of p < 0.05
calculated using a student t test for all three samples) (D) Viperin limits HCV replication.
Huh-7 cells were transfected with pLNCX2-viperin 24 hrs pre-JFH-1 infection (MOI=0.03)
and immunofluorescence staining performed 48 hrs later using a rabbit polyclonal anti-
viperin antibody and a mouse monoclonal anti-NS5A antibody, followed by an Alexa488-
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conjugated goat anti-rabbit Ig and a Alexa555 conjugated goat anti-mouse Ig secondary
antisera. Red cells are stained for NS5A antigen, and green cells are expressing viperin, with
dual labeled cells indicated by arrow heads. (E) shRNA-mediated inhibition of IFN induced
viperin expression in Huh-7 cells. Polyclonal Vip-shRNA cell line #5 and its control were
infected with JFH-1 (MOI=0.03) and then treated with IFN-α 24 hrs post infection for 16
hours before real-time PCR was performed on extracted RNA. (Data are represented as
mean + SEM, *p < 0.001 for Vip-shRNA cell line #5 vs the control at the indicated
treatments) (F) Viperin knockdown reduces the anti-HCV activity of IFN. The polyclonal
Vip-shRNA cell line #5 and its control were either pre-treated (24 hrs) prior to JFH-1
infection (MOI=0.03) or post-treated 24 hrs following infection for 16 hrs with 50 U/ml
IFN-α. RNA was analysed using Real-time PCR. (Data are represented as mean + SEM,
with a significance of p < 0.05 for control cells vs viperin shRNA in the pre- and post-IFN
calculated using a student t test)
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Figure 2. Viperin co-localises with HCV core and NS5A proteins
(A and B) Huh-7 cells were infected with JFH-1 (MOI=0.03) for 72 hrs, before being
transfected with pLNCX2-viperin. Cells were stained 24 hrs following transfection with a
rabbit polyclonal anti-viperin antibody,or a mouse monoclonal anti-core or anti-NS5A,
followed by an Alexa555-conjugated goat anti-rabbit Ig or an Alexa555 conjugated goat
anti-mouse Ig secondary antisera. The boxed region is shown enlarged in panel B, with
arrows indicating co-localisation of viperin and NS5A in putative RC (LD = lipid droplet).
(C) NNeo3-5B cells were transfected with pLNCX2-viperin and stained as above 48 hours
later.
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Figure 3. Viperin displays positive FRET with HCV core and NS5A
Huh-7 cells were infected with JFH-1 (MOI=0.03) for 48 hrs, before being transfected with
pLNCX2-viperin or co-transfected with pLNCX2-viperin and pEGFPC1-ADRP. 24 hrs post
transfection cells were stained with either a rabbit polyclonal anti-viperin antibody followed
by an Alexa555-conjugated goat anti-rabbit Ig and (A) a biotinylated goat anti-GFP
antibody and a CY5 conjugated rabbit anti-goat Ig, (B) a mouse monoclonal anti-core
antibody followed by a CY5 goat anti-mouse Ig or (C) a mouse monoclonal anti-NS5A
followed by a CY5 goat anti-mouse Ig. Slides were analysed on a Zeiss Axioplan
microscope for FRET, with a representative cell displaying a positive FRET signal shown
for each experiment . (Data are represented as mean +/- SEM with a significance of p <
0.001 for (B) and (C)).
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Figure 4. Viperin N'- and C'- terminal mutants are not anti-viral
(A) Schematic diagram of viperin and mutant derivatives. (B) Analysis of the anti-HCV
activity of the viperin mutants. Huh-7 cells were transfected with pLNCX2-viperin or the
indicated mutant viperin plasmid and 24 hrs later infected with JFH-1 (MOI=0.03) for 24 hrs
before RNA harvest and real-time PCR analysis. (Data are represented as mean +/- SEM, *p
< 0.05) (C) N-terminal mutants of viperin have altered localisation. Huh-7 cells were
transfected with pLNCX2-viperin or one of the 6 pLNCX2-viperin truncation mutants. Cells
were stained 24 hrs following transfection with either a rabbit polyclonal anti-viperin
antibody followed by an Alexa488-conjugated goat anti-rabbit Ig or in the case of the C-
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terminal mutants, a mouse monoclonal anti-FLAG antibody followed by an Alexa488-
conjugated goat anti-mouse Ig antisera.
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Figure 5. The C terminus of viperin is important for its interaction with HCV core and NS5A
Huh-7 cells were infected with JFH-1 (MOI=0.03) for 48 hrs, before being transfected with
viperin 3′Δ17. 24 hours post transfection cells were stained with a rabbit polyclonal anti-
FLAG antibody followed by an Alexa555-conjugated goat anti-rabbit Ig and (A) a mouse
monoclonal anti-NS5A antibody followed by a CY5 goat anti-mouse Ig or (B) a mouse
monoclonal anti-core antibody followed by a CY5 goat anti-mouse Ig. Slides were analysed
on a Zeiss Axioplan microscope for FRET. (Data are represented as mean +/- SEM).
Helbig et al. Page 17













Figure 6. Viperin inhibits HCV RNA replication but not IRES activity
Huh-7 cells were transiently transfected with pLNCX2-viperin, pLNCX2-viperin3′Δ17 or
empty vector 24 hours prior to RNA transfection with (A) SGRm-JFH1BlaRL.
Representative transfections efficiencies of the viperin plasmids are demonstrated in (Data
are represented as mean +/- SEM, *p < 0.05) (B). The effects of viperin on HCV IRES
activity were ascertained via transient transfection of the HCV-IRES plasmid pRLHL with
either pLNCX2 or pLNCX2-viperin into Huh-7 cells. Luciferase readouts were taken 24
hours after transfection and were controlled by renilla expression driven from the . (Data are
represented as mean +/- SEM)
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Figure 7. Viperin interacts with the HCV RC factor VAP-A
(A) Huh-7 cells were transiently transfected with pLNCX2-viperin and either pLenti6-
mCherry-Rab5a, Halo-PI4K-IIIα or pLenti6-mCherry-VAP-A. 24 hrs post transfection, the
Halo-TMR ligand (Promega) was mixed with the cells expressing PI4K-IIIα for 15 min
before being washed out and all cells fixed. Cells were stained for viperin using a mouse
monoclonal anti-FLAG antibody followed by an Alexa488-conjugated goat anti-mouse Ig
antisera.
(B) NNeoC-5B cells were co-transfected with pEGFP-viperin and pLenti6-mCherry-VAP-
A. 24 hrs post transfection cells were fixed and the slides were analysed on a Zeiss Axioplan
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microscope for FRET, with a representative cell displaying a positive FRET signal shown.
(Data are represented as mean +/- SEM with a significance of p < 0.001).
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